SCHEMBL4970834

SCHEMBL4970834

Clc1cccc2c1CCN(Cc1c[nH]cn1)C2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
ACACB O00763 1/20 0.45
ADRA2A P08913 2/20 0.44
ADRA2B P18089 2/20 0.44
ADRA2C P18825 2/20 0.44
CYP2D6 P10635 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
DRD2 P14416 2/20 0.41
HTR1A P08908 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR7 P34969 1/20 0.41
HRH1 P35367 1/20 0.41
DRD3 P35462 1/20 0.41
HTR2B P41595 1/20 0.41
PRMT5 O14744 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3529275 0.77 NOTUM (0.39) ADRA2AADRA2BADRA2CCYP2D6ADRA1D
SCHEMBL2407663 0.76 TSHR (0.33) ADRA2AADRA2BADRA2CCYP2D6ADRA1D
SCHEMBL30361133 0.76 TSHR (0.33) ADRA2AADRA2BADRA2CCYP2D6ADRA1D
SCHEMBL3530642 0.74 NOTUM (0.39) ALDH1A1ADRA2AADRA2BADRA2CCYP2D6
SCHEMBL26027881 0.73 ADRA2A (0.58) ALDH1A1GAAACACBADRA2AADRA2B
SCHEMBL6370118 0.72 ADRA2A (0.57) ALDH1A1GAAACACBADRA2AADRA2B
SCHEMBL23972326 0.72 ACACB (0.61) ALDH1A1GAAACACBADRA2AADRA2B
SCHEMBL6967728 0.71 CD44 (0.39) ALDH1A1GAAADRA2AADRA2BDRD2
SCHEMBL26027594 0.70 ACACB (0.71) ACACBADRA2AADRA2BADRA2CCYP2D6
SCHEMBL26027598 0.69 ACACB (0.54) ALDH1A1GAAACACBADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008132139-A2 NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS UCB PHARMA S.A. (BE) 2008-11-06 WO disclosed